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Abstract
Objectives: To present an update on the status of poliomyelitis worldwide, number of cases per year, regions
most affected by the disease, vaccines currently available, their risks and benefits, monovalent vaccine use, risks
of disseminating a mutant virus in the community, progress that has been made in terms of worldwide eradication
and the World Health Organizations (WHO) proposals in this transition period between global eradication and the
post-eradication period.
Sources of data: Data for the period from 1955 to 2005 were searched in MEDLINE, LILACS, The Web, Doctors
Guide, WHO website and Pan American Health Organization (PAHO) website and text book.
Summary of the findings: In 1988, the WHO established the goal of eradicating the disease and interrupting
transmission of the wild virus globally. Since then, there has been a dramatic decline of the disease, although in 2005
there were still some countries considered endemic and others where polio returned on account of imported viruses.
The vaccines used worldwide are the classical tOPV and IPV, and in this eradication process, the use of mOPV
vaccines has been encouraged in places where only one type of poliovirus circulates. In addition to spreading the
virus in the community, the OPV vaccines may, however, cause paralyses by reversal of the neurovirulence process.
Conclusions: For a world free of poliomyelitis disease, it would be necessary to interrupt circulation of the virus,
which will only be possible if the OPV virus were to be discontinued, in accordance with the WHO proposals for this
transition period and the post-eradication period.
J Pediatr (Rio J). 2006;82(3 Suppl):S75-82: Poliomyelitis, OPV vaccine, IPV vaccine, eradication of polio, polio
epidemic, poliomyelitis, World Health Organization.
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Introduction
In May 1988, when approximately 350,000 cases of
poliomyelitis occurred in the world, the World Health
Organization (WHO) established the goal of eradicating
the disease by the middle of the new century and
interrupting transmission of the wild virus globally.
In this process, the oral poliomyelitis vaccine (trivalent
OPV) played a fundamental role, both because it was easy
to administrate, favoring high vaccine coverage rates, and
because of greater vaccine virus fecal-oral transmission.
Three types of wild viruses, known as type 1, type 2 and
type 3, cause poliomyelitis. As part of the initiative for
global eradication of the disease, the main weapon against
them was the so-called trivalent vaccine (tOPV), synthesized
from the three types of live and attenuated viruses. When
there is more than one type of virus circulating in one and
the same community, tOPV is epidemiologically and
operationally the best vaccine to use. When this vaccine is
used, however, there is competition among the three
types of viruses, and the end result is that it causes
protection that is not equally efficient for each type of
virus. Protection against polio type 2 is the most easily
developed. Wild poliovirus type 2 circulation was interrupted
in 1999. At present, only wild polioviruses 1 and 3 circulate
in critical areas for the disease (poliovirus type 3 still
circulates in India, northeastern Nigeria, Southeast of
Niger and Afghanistan).1
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Table 1 - Number of poliomyelitis cases in November 2005
Total number of cases in the world 1,469
Nigeria (endemic) 544
Yemen (importation) 473
Indonesia (importation) 283
India (endemic) 45
Somalia (importation) 37
Sudan (re-established transmission) 26
Pakistan (endemic) 19
Ethiopia (importation) 17
Angola (importation) 9
Niger (endemic) 5
Afghanistan (endemic) 4
Mali (importation) 3
Chad (re-established transmission) 1
Camaroon (importation) 1
Eritrea (importation) 1
Nepal (importation) 1
Status of poliomyelitis in the world
The WHO resolution to eradicate the disease by the
middle of the new century had a dramatic impact on the
disease incidence rates. Of the six WHO regions, namely,
Africa, America, East of the Mediterranean, Europe,
Southeast Asia and the West Pacific, only three of them
(Americas in 1994, West Pacific in 2000, Europe  in 2002)
were able to obtain their eradication certificate, that is, 3
years free of poliomyelitis caused by the wild virus, under
a strict system of active epidemiologic surveillance.2
Southeast Asia presented a decline of over 94% in the
number of cases, that is, from 25,253 cases in 125
countries (polio 1, 2 and 3) in 19883 to 1,600 confirmed
cases (polio 1 and 3) in 2002 and 225 cases in December
2003.4 In the beginning of 2005, the number of notified
cases of the disease worldwide had been substantially
reduced (over 99%), with only six countries still maintaining
endemic poliomyelitis from the wild virus (Nigeria and
India with the highest number of cases; Pakistan, Niger,
Afghanistan and Egypt with a small number of cases).
Indias example was significant.5 In 2002 and 2003, this
country had the highest number of cases in the world, and
Nigeria was ranked second, with 1,517 and 180 cases,
respectively. Teamwork by an aware volunteer population
enabled thousands of children to be vaccinated, resulting
in a substantial decrease in the number of cases in India,
to 224 by the end of 2003. In 2004, the number of polio
cases in India was 1345 and, on May 30, 2005, it had fallen
to only 15,4,5 a very encouraging figure achieved in 2
years. In Nigeria, however, religious leaders, claiming
that the polio vaccine transmitted the AIDS virus and
caused infertility, forced the immunization program to be
suspended. As can be imagined, the number of polio cases
increased greatly, making it possible for the virus to be
exported to various countries in the world. In the beginning
of 2005, in addition to the six countries with endemic polio,
there were 18 countries with polio from the imported
virus. At present, there are more cases of polio from
imported viruses than from endemic polio.
In 2003/2004, due to the increased number of cases
in Nigeria, with wild virus transmission to other previously
poliomyelitis-free countries, a massive vaccination
campaign was launched in Africa and Asia. This campaign
reached 45 countries, in which 375 million children were
vaccinated with tOPV vaccine. These campaigns were
intensified in 2005, with the WHO proposal to eradicate
the disease by the end of the year. The affected countries
are making an effort to eliminate the problem. In April
2005, importation of poliovirus type 1 from Saudi Arabia
and the Sudan, countries with extremely low populational
vaccine coverage, resulted in an important outbreak in
Indonesia, after 10 years without wild poliomyelitis.6 This
was extremely worrying, and emphasized the need for
maintaining high vaccine coverage and excellent quality
epidemiologic surveillance, in addition to maintaining
routine immunization with OPV or IPV. Another country
with a significant number of cases on account of poliovirus
importation was Yemen. After various actions, with national
immunization days with mOPV1, the epidemic is considered
under control.7
On November 1, 2005, the number of poliomyelitis
cases in the world was 1,4698 (Table 1). It is noted that
Egypt no longer appears on this list, although it is still
listed as one of the six countries in which wild polio is
endemic (Nigeria, India, Pakistan, Niger, Afghanistan and
Egypt). After mOPV1 vaccine was used in the campaigns,
the last case of wild polio reported in Egypt was in January,
2005. The WHO considers that the main challenge in terms
of eradication continues to be Nigeria, requiring some
additional months of intensive work to break the
transmission chain.9
Types of poliomyelitis vaccines available
The large paralytic poliomyelitis epidemics were
controlled thanks to the advent of efficient vaccines that
constituted the only means of preventing the disease.
There are two types of vaccines available, which differ as
regards administration and immunologic mechanism:
injectable inactivated poliovirus vaccine and oral attenuated
poliovirus vaccine.
Inactivated poliomyelitis vaccine
The inactivated poliovirus vaccine (IPV), developed by
Salk in 1954, was the first to be licensed and used initially
in the USA. The authors demonstrated that the poliovirus,
by incubation with formalin 1/1,000 in a 12 to 14 day
Inactivated polio vaccine  Carvalho LHF & Weckx LY
Jornal de Pediatria - Vol. 82, No.3(Suppl), 2006  S77
period, at a temperature of 37 ”C, pH 7, became inactivated,
but maintained adequate antigenic power.10
The first inactivated vaccines containing the three
types of poliovirus used monkey kidney cell cultures, a
limiting factor for large scale production. Furthermore, for
safety, they had their immunogenicity diminished after
the Cutter incident, when various cases of paralysis were
associated with administration of two lots of incompletely
inactivated vaccines.11 In spite of the considerable impact
on the incidence of poliomyelitis, the injectable vaccine
was gradually replaced with the oral attenuated poliovirus
vaccine. To this day some countries maintain the exclusive
use of the inactivated vaccine with good results.
With the advances in cell culture, virus purification and
concentration methods, it has become possible to produce
highly potent inactivated poliovirus vaccine (eIPV,
denominated IPV in this paper) on an industrial scale, with
consequent cost reductions. The new vaccine, started at
the age of 2 months, is able to provide protective antibody
levels with only two doses.12,13 The immunity developed
by the inactivated poliovirus vaccine is essentially of the
humoral type. The vaccine does not compete with the wild
polio virus at intestinal level. Studies have shown that
after parenteral eIPV administration, there is moderate
secretory IgA production in the nasopharynx,14 and
experimental studies in monkeys suggest that some
degree of immunity is induced at intestinal level, by a
mechanism that has not yet been explained.15
Because it contains dead viruses, this vaccine immunizes
exclusively the vaccinated individual and there is no
secondary immunization among contacts. In compensation,
there is also no risk of generating mutant viral strains,
capable of producing occasional cases of paralysis
associated with the vaccine. IPV may, therefore, be used
safely in immunosuppressed patients.16,17
In our environment, as is the case in most developing
countries, routine poliomyelitis vaccination is done with
oral attenuated live virus vaccine, the inactivated vaccine
being indicated only for individuals who present some
contra-indication for receiving oral vaccine.
Basically, IPV is indicated and available in Brazil in the
Special Immunobiology Referral Centers (CRIE  Centros
de ReferŒncia para Imunobiológicos Especiais) for:
 Immunosuppressed individuals in general  primary
immunodeficiencies, HIV infection (asymptomatic or
symptomatic), neoplasias, immunosuppression,
chemotherapy drug or radiotherapy, bone marrow
transplant.
 Home contacts of immunosuppressed individuals.
Oral poliomyelitis vaccine
After successive passages in an animal host, Sabin
developed attenuated strains of the three types of poliovirus
with loss of neurovirulence, maintaining the infection
capacity in the gastrointestinal tract, and immunogenic
capacity.18
Attenuated poliovirus vaccine (OPV) is administered
orally, and similarly to infection by the wild polio virus, it
produces both local immunity at mucosa level and humoral
immunity.19 Released for use in the USA in 1962, OPV
gradually supplanted inactivated poliovirus vaccine (the
old IPV) thanks to its superiority in terms of immunogenic
capacity, the ability to induce local class IgA antibody
production in the oropharynx and the gastrointestinal
tract, in addition to being low cost and easy to administer.20
In addition to the immunity produced, the vaccine
virus competes with the wild polio virus to occupy the
coupling sites in intestinal lumen, and is therefore very
efficient in blocking outbreaks.21 Vaccination viruses that
colonize the intestines are excreted in large quantities in
the feces and may secondarily infect the vaccinated
individuals susceptible contacts, producing immunity in
them as well. The capacity of attenuated strains to spread
contributes to a higher rate of immunization than that
provided by vaccination coverage.22 This knowledge
provides the basis for mass vaccination campaigns,
successfully implemented in various regions of the world.
Attenuated anti-poliomyelitis vaccine may be presented
in trivalent (containing the three types of poliovirus),
bivalent (containing two types) or monovalent (containing
only one type) suspensions, the trivalent form being used
for routine immunization.
In the majority of susceptible children who receive oral
vaccine, the virus persists in the oropharynx for 1 to 2
weeks and is excreted in the feces for a period of up to 2
months, the excretion peak being in the first week after
administration.23
As is the case with other live virus vaccines, OPV is
thermo-unstable, and great loss of potency occurs through
heat. Of the three strains, P3 is the most thermo-unstable,
losing potency some hours afterwards at temperatures
above 10 ”C. Therefore, it is fundamental to maintain an
adequate cold chain to guarantee the vaccines full
immunogenicity. One of the problems noted with the use
of the vaccine is the low rate of seroconversion obtained
with oral vaccine administration in tropical countries.
Whereas in temperate climate countries over 95%
seroconversion is obtained, in tropical climate countries
various studies have shown seroconversion rates as low as
50%,24,25 and additional doses are necessary for
seroconversion.26 A review of oral vaccine immunogenicity
studies in developing countries showed that on an average,
after three doses of VOP, only 73, 90 and 70% are
protected against the polioviruses P1, P2 and P3
27
respectively. Probably, oral anti-polio vaccine thermo-
instability,28 and mainly, the interference of other
enteroviruses contribute to this.29
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VAPP Poliomyelitis from the OPV vaccine
Recent exposures to the virus
Virologically and epidemiologically independent
episodes
cVDPV Circulating poliomyelitis virus derived from OPV vaccine
[> 1% of diversity from the nucleotidic sequence of the
Sabin strain indicating prolonged replication with or
without circulation in (VDPV)]. They can be isolated
from healthy individuals or from the environment.
They may also occur in outbreaks involving a
transmission chain by the dissemination of this new
specific mutant virus.
iVDPV Poliomyelitis virus derived from OPV vaccine, in
immunosuppressed individuals
Table 2 - Poliovirus definitionsThere have been recent examples, such as various
cases of wild poliomyelitis that occurred in Cape Verde in
children vaccinated with three doses of OPV. In India, in
2001, in accordance with WHO reports of 268 confirmed
cases of wild polio, 23% had received 4-5 doses of OPV
and 36% had received more than five doses of OPV. In
addition to these considerations, it is known that intestinal
immunity caused by IPV vaccine is less consistent and less
lasting than intestinal immunity caused by OPV vaccine.
Intestinal immunity that occurs after OPV is serotype-
specific, and is more immunogenic for serotype 2.30 For
serotypes 1 and 3, supplementary immunization campaigns
with several doses of OPV are required for routine
immunization.
Both vaccines provide collective immunity because
they diminish wild virus transmission (herd immunity).
Herd immunity was well demonstrated, even with the
old IPV vaccine, with a lower antigen content.31,32 As
previously explained, however, IPV vaccine does not
allow the vaccination virus to be disseminated and OPV
vaccine does. This frequently convenient dissemination,
in accordance with the epidemiologic situation, may
become a problem. And this is exactly what is currently
being discussed.
Risk associated with OPV vaccine use
Although the benefits of OPV vaccine are very well
known, some adverse events associated with its use may
occur.
The vaccination viruses are derived from wild virus
strains with extremely reduced neurovirulence and
transmissibility. During replication, the vaccination virus
may undergo reverse mutation with increase in
neurovirulence, and may cause rare cases of vaccine-
associated paralytic poliomyelitis (VAPP) in both
vaccinated individuals and non-vaccinated contacts. If,
in addition to neurovirulence, transmissibility is also re-
acquired, as occurs with the circulating vaccine-derived
poliovirus (cVDPV), outbreaks of paralysis associated
with the vaccine may occur. The definitions of the events
associated with OPV and their causes appear in Table 2.
The main adverse event associate with OPV is post-
vaccination paralysis, both in vaccinated individuals and
contacts. The risk of paralysis is substantially greater in
the first dose of OPV than in subsequent doses. In
immunosuppressed individuals, this risk is even higher,
around 3,200 times higher than in immunocompetent
individuals.33 A cooperative study conducted by the WHO
in 13 countries showed a rate of one case of paralysis
associated with the vaccine for each 3.2 million doses
distributed, both in vaccinated and contact individuals.
Data in the USA estimated one case for 2.4 million doses
distributed, the risk being 1/750,000 in the first doses and
1/5.1 million in subsequent doses.34
In Brazil, the incidence of poliomyelitis associated with
vaccine has been low. Between 1988 and 2003 (15 years),
40 confirmed cases of poliomyelitis associated with oral
vaccine were registered, basically in children, with
predominance in the first and second doses. The estimated
risk in studies on the first dose ranged from one case in 1.2
million to one case in 2.4 million doses applied, and for all
the doses, it ranged from one case in 3.6 million to one
case in 13 million doses applied.35
According to the Pan-American Health Organization
(PAHO) and WHO, there are two types of poliomyelitis
related to the vaccine:36
 Case of poliomyelitis associated with vaccine: Flaccid
and acute paralysis that starts between 4 and 40 days
after receiving OPV, and that presents neurological
sequelae compatible with poliomyelitis 60 days after
the onset of motor deficit.
 Case of poliomyelitis associated with vaccine in contacts
(those in communication): Flaccid acute paralysis that
appears after contact with a child receiving OPV up to
40 days previously. The paralysis appears between 4
and 85 days after vaccination, and should present
neurological sequelae compatible with poliomyelitis 60
days after the onset of motor deficit.
In any of the cases, it is imperative to isolate the
vaccine poliovirus in stool samples so that the case can
be considered associated with the vaccine. The stool
sample collection is extremely important as early as
possible in the first 14 days after the onset of motor
deficit. But even if stool is collected later, between 15
and 40 days after the onset of motor deficit, and vaccine
virus is isolated, the case will be considered associated
with the vaccine.
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All the polioviruses37 currently isolated are analyzed,
and in accordance with their intratypical differentiation,
they have been sequenced in accordance with the surface
protein of the viral capsid (VP1).38 Isolates with < 1% of
difference from the Sabin strain of the same serotype are
classified as Sabin-like; 1 to 15% difference are classified
as VDPV (if they circulate and cause outbreaks, they are
called cVDPV; if they occur in immunosuppressed
individuals, they are called iVDPV; and if isolated from
patients without immunodeficiencies and not associated
with outbreaks, they are ambiguous aVDPV); and those
with over 15% of difference are classified as wild virus.39
Considering genetic similarities, there is less than 82%
similarity between the wild virus and OPV, and more than
99.5% between the VAPP virus and the vaccination virus.
The excreted viruses that are derived from vaccines
are frequently more virulent than the original OPV strains.
During excretion, mutations and genetic alterations occur
rapidly, in a sequential manner, in response to the
different intestinal pressures. Low levels of immunity in
the population favor the selection and transmission of
vaccine variants with biological properties that are
undistinguishable from those of the wild polioviruses.40-42
As a result of this, a type of virus currently known as
cVDPV appeared, that is, a circulating poliomyelitis virus
derived from the vaccine. It can be isolated in healthy and
immunosuppressed individuals, and from the environment.
The cVDPV is implicated in outbreaks involving a
transmission chain by a specific mutant virus. For example,
the poliomyelitis outbreaks that occurred in China during
the 1990s, due to OPV2, and more recently, in 2004, two
cases; the polio outbreak in Egypt from 1988 to 1993 (32
cases; 93 to 96% genetic similarity to OPV2); the polio
outbreak in Hispaniola (Dominican Republic and Haiti) in
2000/2001 (31 notified cases; 97% genetic similarity to
OPV1) and three cases in the Philippines (97% similarity
to OPV1) in 2001, in addition to four cases in Madagascar
in 2002, and in China in 2004.43 The outbreak in Hispaniola
received great attention in the medical literature,44 and
wide coverage and publicity in the press. Low vaccine
coverage favored conditions for the development of cVDPV
outbreaks.
Although generally associated with outbreaks, VDPV
may be isolated in individuals who are either
immunosuppressed or not, occasionally or not, without
the occurrence of outbreaks. The recent example in the
USA is noted, in which the VDPV virus was isolated in
four non-vaccinated Amish children from a case index
with immunodeficiency. The viruses isolated were derived
from the Sabin poliovirus type1 strain, with 97.7%
genetic similarity.45 Lack of population vaccine coverage
favors dissemination of the viruses (as in the case of
Hispaniola, in which coverage was around 30 to 60% in
200044), and this explains why an outbreak has not
occurred in the USA, at least up to the present time. It
is important to emphasize that in the USA, the vaccination
schedule against poliomyelitis has used exclusively eIPV
since 2000, and since that time there has not been any
case of VAPP.46
It is estimated that mutation occurs in the range of 1%
per year, which indicates that the circulation time for
cVDPV can be inferred from the degree of divergence in
the genetic sequence.37 Failures in vaccination coverage
are critical determinant factors in the occurrence of cVDPV
outbreaks.38 In accordance with recent WHO publications,8
of the 333 confirmed polio cases in Southeast Asia up to
November 2005, 31 were from viruses derived from OPV
vaccines, and of the 528 confirmed cases in Africa, four
were from viruses derived from OPV vaccines.
Another problem to be faced is poliovirus maintenance
in immunosuppressed individuals (iVDPV), as potential
reservoirs, with permanent excretion of the viruses
(which can be over 6 months in a person with severe
primary immunodeficiency).46 Theoretically, the iVDPV
could reintroduce the poliovirus in the general population.
In 40 years of OPV use, however, 28 iVDPV were
documented up to the end of 2004, including one in
Thailand in 2003, without the occurrence of secondary
cases. In four of these cases (all isolated in developed
countries), excretion was prolonged for over 36 months.
On this particular issue, there is also concern about
environmental contamination by vaccination poliovirus
(for example, in the water and sewage networks).47
Continuity of OPV use in the public health context
The WHO estimates that with the eradication of the
wild poliovirus from the world, initially forecast for the end
of 2005, or at a time very close to this, the continued use
of OPV vaccine would compromise the proposal of a
poliomyelitis-free world. This is easy to understand. It is
estimated that the number of VAPP cases will continue to
occur in the proportion of two to four cases per million
births, leading to around 250 to 500 new cases of VAPP per
year. The WHO estimates that the major occurrence of
VAPP should occur in India with a rate of two cases per
million births.43 As regards outbreaks from cVDPV, more
than one outbreak per year is estimated with the
continuation of OPV.6
Thus, the continued use of OPV after interrupting the
wild virus circulation and transmission, becomes
inconsistent with a world free of polio and its eradication.
Until global certification of wild polio eradication is
obtained, there must always be vaccination, either with
OPV or eIPV. Vaccination coverage must be maintained in
the routine schedules and in some cases supplementary
immunization activities, such as vaccination campaigns,
mop-up campaigns, etc.
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As a strategy to eradicate wild polio from places where
it still occurs endemically or from imported viruses, the
WHO has encouraged the development and application of
monovalent OPV vaccines (mOPV).1,48 Studies have shown
that with the same number of doses, mOPV vaccine leads
to greater type-specific immunity when compared with
tOPV. For example, in tropical countries, while 80 and 72%
of the children develop immunity with mOPV1 and mOPV3,
only 40 and 31%, respectively, develop immunity with
tOPV for poliovirus type 1 and for poliovirus type 31 after
the first dose, which represents a great advantage, since
the large majority of wild poliomyelitis cases occur in
children under the age of 2 years. An additional advantage
is that if children immunized with mOPV are later exposed
to the wild virus (of the vaccine serotype), it is expected
that 40% will excrete less virus for a shorter period of
time, thus limiting the possibility of later transmission.
The recent introduction of mOPV1 would seem to have
interrupted transmission in two technically problematic
areas of eradication in the world  Egypt and many areas
of India.7 mOPV1 was first used in April 2005 in India and
subsequently in Egypt.48 The WHO has recommended the
expanded use of mOPV in mop-up campaigns, including in
countries affected by outbreaks, such as Indonesia, Yemen,
Ethiopia, Somalia and Angola.7
IPV vaccine use
The great advantage of IPV vaccine is its excellent
efficiency and safety profile. As far as individual protection
is concerned, IPV vaccine does not cause paralytic
poliomyelitis, VAPP or predisposition to the appearance
of VDPV. It may be associated with other vaccines in
what is called combined vaccines, providing greater
comfort, convenience and adhesion. In addition, no
supplementary doses are required in the primary
vaccination schedule, thus reducing the cost of
innumerable vaccination campaigns, such as those that
accompany OPV vaccine.
At present there are 22 countries in the world that
routinely apply only IPV vaccine in their primary vaccination
schedule. These include the USA, Canada, England and the
majority of European countries. Of these 22, four maintain
one booster dose with OPV. Another seven European
countries have a sequential schedule with two initial doses
of IPV, followed by two doses of OPV.
The great disadvantage of IPV in the polio eradication
context is that there is a limited annual production capacity,
which perhaps does not exceed 100 million doses.49
Production could be increased and the price per dose could
fall, if the manufacturing laboratories could be given
guarantees that there would be an international consumer
market for billions of doses of IPV to be produced in the
post-vaccination era.49
Simultaneous cessation of OPV vaccine use
As a result of the above-mentioned facts, world public
health authorities and the various countries in tandem
with the WHO are currently discussing the eventual
simultaneous global cessation of OPV, after the global
eradication certificate is obtained (3 years without
poliomyelitis, maintaining epidemiologic surveillance at
levels recommended by the WHO). The end objective of
the WHO Polio Eradication Initiative6 is to assure that
transmission of the poliovirus is globally interrupted through
nationally and internationally coordinated action, leading
to humanitarian and economic benefits from this
eradication.6 There are various publications about the
subject which deserve very special attention from the
entire medical community.2,50
The main challenges for a polio-free world are to break
the final transmission chains in endemic countries, to
control outbreaks in countries previously free of the wild
virus, to maintain funding and political commitment, to
control the problem of low vaccination coverage in polio-
free countries and to assure that sufficient stocks of
vaccine are maintained.51
Differently from the anti-smallpox vaccine, the eventual
cessation of OPV use must be synchronized throughout all
the countries that use it. But cessation of OPV also involves
risks, summarized as follows:43
 The immediate risk of cVDPV emergence  this risk
would be greater in the first few months and would be
lower in countries with high vaccination coverage at
the time of OPV cessation, and if the countries were
perfectly coordinated for simultaneous cessation. The
risk is estimated at 65 to 90% in the first year after
simultaneous OPV cessation, dropping to 5 to 15% in
the second year, with reduction to 1 to 5% at the end
of the third year.
 The medium and long-term risk of re-introducing
poliovirus originating from stocks of any nature
(diagnostic laboratory, for example). This risk is small,
if biological material is adequately contained. Even
with poliovirus derived from iVDPV, the risk is very low.
Although they are slight, these risks do exist. Thus, the
WHO proposal to implement strategies that must comply
with a schedule are justified.52 There are six prerequisites
for this simultaneous cessation (WHO):
 Confirmation that global transmission of wild poliovirus
has been interrupted;
 Appropriate containment of biological material
containing poliovirus;
 Maintenance of international stocks of mOPV vaccine
(to control eventual outbreaks in the simultaneous
OPV cessation phase);
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 Maintenance of active, high quality, epidemiologic
surveillance of circulating poliovirus;
 Simultaneous, duly coordinated cessation of OPV;
 Establish a long-term, routine national immunization
policy with IPV, depending on the decision of every
country.
For the countries that use OPV routinely in public
health immunization (even if they also use IPV in combined
vaccines, in immunization through private clinics), the
priorities at this preparatory stage for global cessation of
OPV may be pointed out as follows:43,52
 To reinforce active epidemiologic surveillance of flaccid
acute paralysis, to certify eradication, for eventual
detection of wild poliovirus and/or cVDPV and to detect
the potential appearance of imported poliovirus.
 Implement appropriate contention of wild poliovirus
and poliovirus derived from OPV vaccine. Develop
stocks of mOPV and criteria for its use.
 Maintain high vaccination coverage (> 90%), minimizing
the risk of transmission of imported and/or emergency
cVDPV or VDPV viruses (this vaccination coverage
must be with OPV or IPV, depending on the countrys
immunization policy).
 Decide, after analyses of risks, benefits and costs,
when to interrupt all routine poliomyelitis immunization
after OPV cessation (at this time, the IPV vaccine will
be the only option available for routine immunization).
The WHO recommends that countries that decide to
continue with their routine immunization with IPV,
after global OPV suspension, in addition to analyzing
costs and benefits, should take various factors into
account, such as the impact on the schedule and
control of other diseases, alteration of the pertussis
component in combined vaccines, use of the vaccine
with a different preservative, among other operational
problems as a result of this measure.
 Make an estimate of the risks of iVDPV and establish a
plan to control it, if necessary.
 Prepare national plans and mechanism for cessation of
all OPV used in routine immunization programs, in
addition to destroying remaining stocks of tOPV.
These priorities must comply with a certain sequence,
that is, it is estimated that the post-OPV era should be
reached in 6 to 8 years time.52
Final considerations
The poliomyelitis type 1, 2 and 3 viruses currently in
circulation, derived from OPV, constitute a threat to a
completely poliomyelitis-free world. With polio eradicated,
the trend is to reduce vaccination through carelessness, or
because there are other priorities that deserve immediate
attention. If some countries continue to use OPV, the virus
will continue to circulate, undergo mutations and will find
unprotected populations on a larger or smaller scale,
depending on the vaccination coverage of that group.
Therefore outbreaks of cVDPV will appear, as we have
already seen in various places in the world, and the
problem of poliomyelitis will not be solved.
The operational difficulty of implementing IPV vaccine,
because it is parenteral, in addition to the cost associated
with it, are the reasons given for not adopting it as routine
in immunization programs of developing countries. Perhaps
the use of combined vaccines may make it feasible to
implement IPV vaccine, especially if we think of the
enormous cost of OPV campaigns and the loss of vaccines
that is known to occur. The time has come for us to
schedule a change in the poliomyelitis vaccination policy.
To sum up, eliminating poliomyelitis disease ultimately
requires suspension of the circulating virus. And when
there is no longer any wild poliomyelitis in the world, the
only circulating virus will be the OPV vaccine, which must
be discontinued.
Yes, it is only under these conditions that we will finally
be able to have a poliomyelitis-free world!
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